IQVIA Holdings Inc. (NYSE:IQV) Holdings Decreased by Congress Asset Management Co. MA

Congress Asset Management Co. MA trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 26.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 945 shares of the medical research company’s stock after selling 335 shares during the quarter. Congress Asset Management Co. MA’s holdings in IQVIA were worth $239,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Lazard Asset Management LLC grew its stake in IQVIA by 2.9% during the 3rd quarter. Lazard Asset Management LLC now owns 2,889,263 shares of the medical research company’s stock worth $568,460,000 after buying an additional 80,189 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in IQVIA by 4.0% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,418,392 shares of the medical research company’s stock worth $532,070,000 after buying an additional 93,194 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in IQVIA by 339.6% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock worth $478,308,000 after buying an additional 1,597,003 shares during the last quarter. Capital Research Global Investors boosted its position in IQVIA by 42.2% during the 4th quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock worth $461,675,000 after acquiring an additional 592,372 shares during the period. Finally, Wellington Management Group LLP boosted its position in IQVIA by 1.0% during the 3rd quarter. Wellington Management Group LLP now owns 1,816,266 shares of the medical research company’s stock worth $357,350,000 after acquiring an additional 17,139 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on IQV shares. Leerink Partnrs reiterated an “outperform” rating on shares of IQVIA in a research report on Monday, February 26th. SVB Leerink started coverage on IQVIA in a research report on Monday, February 26th. They set an “outperform” rating and a $290.00 price target for the company. The Goldman Sachs Group started coverage on IQVIA in a research report on Thursday, June 6th. They set a “buy” rating and a $270.00 price target for the company. Robert W. Baird reduced their price target on IQVIA from $254.00 to $245.00 and set a “neutral” rating for the company in a research report on Friday, May 3rd. Finally, Evercore ISI cut their price objective on IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a report on Friday, May 3rd. Four equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus target price of $258.40.

IQVIA Trading Up 1.0 %

Shares of NYSE IQV opened at $216.25 on Monday. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The company has a market cap of $39.40 billion, a price-to-earnings ratio of 29.54, a P/E/G ratio of 1.95 and a beta of 1.53. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. The business has a fifty day simple moving average of $225.57 and a 200-day simple moving average of $230.38.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, May 2nd. The medical research company reported $2.30 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.11. The firm had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.